With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.

Envision a simple blood test that can detect the presence of Alzheimer’s disease up to 10 years in advance of a standard clinical diagnosis. NanoSomiX Inc. is developing technology that evaluates brain-derived exosomes and reveals biological changes that are implicated in the pathogenesis of AD.

The emerging life sciences companies profiled in the November issue of Start-Up: ImmuneXcite, Inivata, Lumoptik, NanoSomiX, and Scholar Rock.

Envision a simple blood test that can detect the presence of Alzheimer’s disease up to 10 years in advance of a standard clinical diagnosis. NanoSomiX Inc. is developing technology that evaluates brain-derived exosomes and reveals biological changes that are implicated in the pathogenesis of AD.